Authors
Latest:
The FRESH Study Tests New HIV Remission Strategy in South African WomenThumbi Ndung'u, BVM, PhD discussed the safety and partial virologic control observed in a Phase 2a trial using broadly neutralizing antibodies and vesatolimod in HIV treatment interruption.
Latest:
What to Make of Changing COVID-19 Vaccine Indications and GuidanceJeremy Faust, MD, discusses what he and other providers are dealing with in the face of conflicting guidance and actions from the federal agencies.
Latest:
A Chance to Improve Hepatitis C Care for PWIDHere is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential challenges in applying it in the United States.
Latest:
Imdusiran for Chronic Hepatitis B Achieves Functional Cure in 50% of PatientsArbutus CEO Michael McElhaugh discussed trial results showing that a combination of imdusiran, an RNAi therapeutic, and pegylated interferon alfa-2α can achieve a functional cure in chronic hepatitis B patients.
Latest:
High-Resistance Therapy Options for Treatment-Naïve Patients With HIVJoseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss the likelihood of other combination regimens for the treatment of multidrug-resistant HIV, including monoclonal antibodies.
Latest:
Resolution of Scurvy in a Patient With a Spinal Cord InjuryAt 7.1%, vitamin C deficiency in the US is rare. Unfortunately, identifying scurvy is complex, frustrating, and time-consuming for both patient and provider.
Latest:
Ivermectin Does Not Reach Primary Endpoint in Burkina Faso Malaria TrialSunil Parikh, MD, MPH, discusses the trial’s findings, noting no significant difference in malaria incidence (1.78 vs 1.84 cases per 100 person-weeks).
Latest:
Oral Therapeutic Options to Prevent Disease Progression From COVID-19 in an Ambulatory SettingAs the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.
Latest:
Advances in Mini Gut Organoid Models Reveal Key Insights into Norovirus ReplicationSasirekha Ramani, PhD on creating a broad-spectrum antiviral that could be effective in various clinical settings, especially given the emergence of new and more dominant strains.
Latest:
A Penicillin Allergy Questionnaire for Outpatient ClinicsClinicians developed an algorithm and screening questionnaire for outpatient penicillin allergy evaluation, designed to stratify patients into high- and low-risk penicillin allergy groups. Here is the sample questionnaire to consider for use in clinics.
Latest:
The Roles of Misinformation, Disinformation, and Confirmation Bias in Public Health DiscourseKatrine Wallace, PhD, and Eric John Burnett, MD, discuss the distinctions between them and strategies to understand better the information people are consuming.
Latest:
Ready, Set, Cabenuva: Implementing Cabotegravir/RilpivirineThis novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.
Latest:
When Climate Change Gets Personal: The Expanding Threat of Mosquito HabitatsAs someone who lives with the long-term effects of chikungunya, Camillo Mora PhD, sees the expanding habitat of mosquitos and is concerned more people will be exposed to vector-borne illnesses and deal with not only the acute phases of these viruses but also the possibility of long-term health effects they can present.
Latest:
Unmasking the Infodemic: The Impact of COVID-19 Misinformation on Public HealthSocial media platforms, public health agencies, and communities must join forces to stop the rapid spread of false information.
Latest:
Climate Change Effects on Vector-Borne Disease: The Case of LymeWith evolving weather patterns, the natural habitat of ticks is expanding, and more people are becoming susceptible to them.
Latest:
Emerging Infectious Diseases During COVID-19In this era of increasingly mobile and connected populations, it is possible for an infection to spread around the world in 24 to 48 hours.
Latest:
Ceftolozane/Tazobactam Shows Strong Activity Against ESBL E coli, But Gaps Remain for K pneumoniaeAt MAD-ID, Jose Alexander, MD, reports 98% susceptibility in ESBL E coli and 76% in K pneumoniae, underscoring the need for species-specific testing.
Latest:
Doravirine and Islatravir Combination Shown to be Noninferior to Once-Daily ARTIn a blinded phase 3 study, doravirine and islatravir was compared to antiretroviral therapy, BIC/FTC/TAF (Biktarvy), and it was shown that there was no between-group differences in mean change in CD4 T-cell or total lymphocyte count at week 48.
Latest:
Bictegravir vs Darunavir in Advanced HIV: Results from the LAPTOP TrialGeorg Behrens, MD, PhD, highlights superior virological suppression and immune recovery with bictegravir-based therapy in therapy-naïve individuals with advanced HIV disease.
Latest:
Are We at a Breaking Point for Adoption of Updated Susceptibility Interpretive Criteria?The implementation of new College of American Pathologists rules presents an opportunity for collaboration between clinical microbiology laboratories and infectious disease pharmacists and physicians.
Latest:
The Future and Resources in HCV CareExpert hepatologists discuss future developments in HCV that they are excited about and provide resources for new providers to get started on delivering HCV care.
Latest:
The Overlooked Tropical Diseases You May Not Know AboutOver 1 billion people are estimated to be affected by 20 conditions of neglected tropical diseases (NTDs), though they are often unheard of by many. Heather Saunders, MPH, RN, CIC, delves into 5 of these diseases and discusses efforts to stop their spread.
Latest:
HIV: Treating Patients with Viral MutationsSorana Segal-Maurer, MD, offers clinical insights on treating patients with HIV who have viral mutations, including M184V, highlighting guideline recommendations.
Latest:
Clinicians Discuss the State of Vaccines TodayA panel discusses how vaccine policy under new federal government policies, why misinformation has flourished and what individual providers can do to win back patient trust.
